S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

INTS Intesity Therapeutics Inc

2.32

0.00 (0.00%)

Pre Market

Last Updated: 03:05:14

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Intesity Therapeutics (NASDAQ:INTS)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Intesity Therapeutics Charts.

Intesity Therapeutics (NASDAQ:INTS)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Intesity Therapeutics Charts.

Intesity Therapeutics Inc News

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
Tuesday 28 January 2025 (2 weeks ago) • PR Newswire (US)

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
Friday 10 January 2025 (1 month ago) • PR Newswire (US)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Monday 30 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Friday 20 December 2024 (2 months ago) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Friday 13 December 2024 (2 months ago) • Edgar (US Regulatory)

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer
Thursday 12 December 2024 (2 months ago) • PR Newswire (US)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Friday 22 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 21 November 2024 (3 months ago) • Edgar (US Regulatory)

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Thursday 21 November 2024 (3 months ago) • PR Newswire (US)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Wednesday 20 November 2024 (3 months ago) • Edgar (US Regulatory)

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Monday 18 November 2024 (3 months ago) • PR Newswire (US)

Form 8-K - Current report
Wednesday 13 November 2024 (3 months ago) • Edgar (US Regulatory)

More Intesity Therapeutics Inc News Articles

TPT Global Tech (CE)

Kraig Biocraft Laborator... (QB)

Spectra7 Microsystems

RespireRx Pharmaceuticals (CE)

Greater Cannabis (PK)

Intergrated Cannabis Sol... (PK)

Moon Equity (PK)

Virexit Technologies (PK)

Super Micro Computer

Bioelectronics (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions